Meeting
2024 ASCO Annual Meeting
A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Authors
John C. Byrd
University of Cincinnati, Cincinnati, OH
John C. Byrd , Pierluigi Porcu , Thomas Sundermeier , Takashi Nakada , Takeyuki Iwata , Sergio Prados , Leo I. Gordon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05515406
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS7083)
DOI
10.1200/JCO.2024.42.16_suppl.TPS7083
Abstract #
TPS7083
Poster Bd #
66a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.
First Author: Elise A. Chong
Poster
2023 ASCO Annual Meeting
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
First Author: Jianxiang Wang
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe